Drugs / ImmuneCellVir-I
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06011486 | Jun 2024 → Jun 2025 overdue | cytomegalovirus infection | Hospital Israelita Albert Einstein | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ImmuneCellVir-I | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06011486 ↗ |
| Route | Intravenous | “Cytomegalovirus (CMV)-specific lymphocytes will be administered intravenously.” NCT06011486 ↗ |